beta-cryptoxanthinWhat was measured
Measured, with no finding
77 endpoints
Show what was measuredHide what was measured
bone turnover markers
decreases
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers
PMID 24909799 · one of two readings recorded this
HDL cholesterol (c-HDL)
decreases
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers
PMID 24909799 · one of two readings recorded this
LDL cholesterol (c-LDL)
decreases
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers
PMID 24909799 · one of two readings recorded this
order of intervention, previous treatment and their interaction (carryover)
no effect
Intervention caused changes in almost all the markers while the order, previous treatment and the interaction did not reach statistical significance
PMID 24909799 · one of two readings recorded this
serum β-cryptoxanthin, β-sitosterol and campesterol
increases
The intake of beverages containing β-Cx and PS brought about a significant increase in serum levels of β-Cx, β-sitosterol and campesterol
PMID 24909799 · one of two readings recorded this
total cholesterol, c-HDL, c-LDL and bone turnover markers after beverage with beta-cryptoxanthin (0.75 mg/day) and phytosterols (1.5 g/day), single and combined, crossover
decreases, n = 38
Not recorded as a finding: the intervention held more than the compound
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers.
PMID 24909799 · one of two readings recorded this
total cholesterol, HDL-cholesterol, LDL-cholesterol and bone turnover markers after 4 weeks of beverage (abstract only)
decreases, significant decreases in total cholesterol, HDL-cholesterol, LDL-cholesterol and bone turnover markers with the combined beverage only
Not recorded as a finding: the intervention held more than the compound
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers.
PMID 24909799 · one of two readings recorded this
total cholesterol
decreases
Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers
PMID 24909799 · one of two readings recorded this
increase of post-practice salivary α-amylase activity
decreases
In the β-CRX-group, the increase of post-practice sAA was suppressed in females
PMID 27592828 · one of two readings recorded this
salivary α-amylase activity, post-practice (evening) versus pre-practice (morning)
increases
In the placebo-group, sAA in the evening (post-practice sAA) tended to be higher than sAA in the morning (pre-practice sAA) during both routine daily life at the university and during pharmacy practice
PMID 27592828 · one of two readings recorded this
anti-stress effect dose-dependency in stress-loaded male mice
modulates
The dose-dependency of β-CRX was observed in male mice that were loaded with stress
PMID 31366875 · one of two readings recorded this
salivary α-amylase activity, evening versus morning, during pharmacy practice
no effect
Salivary α-amylase activity (sAA), a marker of sympathetic nervous system activity, was significantly higher in the evening than in the morning in the placebo-group during pharmacy practice, but not in the β-CRX-group
PMID 31366875 · one of two readings recorded this
salivary α-amylase activity, evening versus morning, during pharmacy practice
increases
Salivary α-amylase activity (sAA), a marker of sympathetic nervous system activity, was significantly higher in the evening than in the morning in the placebo-group during pharmacy practice, but not in the β-CRX-group
PMID 31366875 · one of two readings recorded this
adiponectin, 12-week change, HPD-BCX versus control
increases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
high-sensitivity C-reactive protein, 12-week change, HPD-BCX versus control
decreases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
interleukin-6, 12-week change, HPD-BCX versus control
decreases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
malondialdehyde, 12-week change, HPD-BCX versus control
decreases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
serum malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity and adiponectin, HPD-BCX group versus control, 12 weeks
Not recorded as a finding: the intervention held more than the compound
These results show that an energy-restricted HPD supplemented with BCX more efficaciously alleviates oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet.
PMID 31841744 · one of two readings recorded this
serum malondialdehyde, hs-CRP, interleukin-6, total cytokeratin-18 (CK18-M65), total antioxidant capacity and adiponectin, 12-week change (abstract only)
decreases
Not recorded as a finding: the intervention held more than the compound
These results show that an energy-restricted HPD supplemented with BCX more efficaciously alleviates oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet.
PMID 31841744 · one of two readings recorded this
total antioxidant capacity, 12-week change, HPD-BCX versus control
increases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
total cytokeratin-18 (CK18-M65), 12-week change, HPD-BCX versus control
decreases, p = 0.001
mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001
PMID 31841744 · one of two readings recorded this
adherence, number of patients taking at least 90% of prescribed capsules
no effect, p = 0.956, n = 92
Adherence (taking ≥ 90% of prescribed capsules) | 84 (91.3) | 22 (95.7) | 20 (87.0) | 21 (91.3) | 21 (91.3) | 0.956
PMID 33081717 · one of two readings recorded this
adverse events, gastrointestinal discomfort or headache, patient report
no effect, no significant differences in drop-out, adherence and adverse events among study groups
Not recorded as a finding: the sentence is agentless about the compound and compares all four arms together, with no β-cryptoxanthin-versus-control contrast
There were no significant differences in drop-out, adherence, and adverse events among study groups.
PMID 33081717 · one of two readings recorded this
change in serum ALP
decreases, p = 0.005
Multivariable adjusted | − 56.8 [− 70.6; − 43.0] | − 43.9 [− 58.3; − 29.4] | − 30.7 [− 44.7; − 16.7] | − 17.6 [− 31.8; − 3.4] | 0.005
PMID 33081717 · one of two readings recorded this
change in serum ALP
decreases, p = 0.001
Unadjusted | − 57.9 [− 76.0; − 39.9] | − 47.7 [− 68.5; − 26.9] | − 27.1 [− 35.3; − 18.9] | − 16.2 [− 23.2; − 9.3] | < 0.001
PMID 33081717 · one of two readings recorded this
change in serum ALT
decreases, p = 0.001
Multivariable adjusted | − 45.7 [− 49.9; − 41.6] | − 35.2 [− 39.5; − 30.8] | − 28.1 [− 32.4; − 23.9] | − 18.5 [− 22.8; − 14.2] | < 0.001
PMID 33081717 · one of two readings recorded this
change in serum ALT
decreases, p = 0.001
Unadjusted | − 45.3 [− 50.2; − 40.3] | − 34.6 [− 39.2; − 30.1] | − 28.9 [− 35.0; − 22.8] | − 18.7 [− 23.7; − 13.7] | < 0.001
PMID 33081717 · one of two readings recorded this
change in serum AST
decreases, p = 0.014
Multivariable adjusted | − 20.2 [− 23.0; − 17.4] | − 18.4 [− 21.4; − 15.5] | − 15.3 [− 18.2; − 12.4] | − 13.1 [− 16.0; − 10.2] | 0.014
PMID 33081717 · one of two readings recorded this
change in serum AST
no effect, p = 0.603
Unadjusted | − 19.4 [− 25.5; − 13.2] | − 15.9 [− 22.6; − 9.2] | − 17.9 [− 24.3; − 11.4] | − 13.9 [− 19.6; − 8.1] | 0.603
PMID 33081717 · one of two readings recorded this
change in serum GGT
decreases, p = 0.001
Multivariable adjusted | − 30.5 [− 33.9; − 27.2] | − 21.7 [− 25.2; − 18.2] | − 19.8 [− 23.2; − 16.4] | − 14.2 [− 17.6; − 10.8] | < 0.001
PMID 33081717 · one of two readings recorded this
change in serum GGT
decreases, p = 0.001
Unadjusted | − 31.2 [− 35.2; − 27.1] | − 22.2 [− 27.6; − 16.8] | − 19.5 [− 24.0; − 15.0] | − 13.3 [− 16.6; − 10.0] | < 0.001
PMID 33081717 · one of two readings recorded this
clinical remission rate (grade 0 hepatic steatosis)
increases, p = 0.001
82.6% in the HP-diet and β-cryptoxanthin group versus 13.0%, 17.4%, and 0.0% in the HP-diet, β-cryptoxanthin, and control groups, respectively; p < 0.001
PMID 33081717 · one of two readings recorded this
drop-out, number of patients
no effect, p = 1, n = 92
Drop-out (discontinuing the intervention) | 6 (6.5) | 1 (4.3) | 2 (8.7) | 2 (8.7) | 1 (4.3) | 1.000
PMID 33081717 · one of two readings recorded this
hepatic steatosis grade 0 remission rate, abdominal ultrasonography
increases, 17.4% remission in the β-cryptoxanthin group versus 0.0% in control
Not recorded as a finding: no outcome node for hepatic steatosis; the quoted sentence is an all-group comparison, not a β-cryptoxanthin-only versus control contrast
In contrast to baseline, there was also a significant difference in terms of hepatic steatosis at study endpoint among groups so that clinical remission rate in the HP-diet and β-cryptoxanthin group was considerably higher than the other groups (82.6% in the HP-diet and β-cryptoxanthin group versus 13.0%, 17.4%, and 0.0% in the HP-diet, β-cryptoxanthin, and control groups, respectively; p < 0.001).
PMID 33081717 · one of two readings recorded this
liver enzymes and grade of hepatic steatosis, within-group reduction
decreases, p = 0.01
Pairwise within group comparisons showed significant reduction of serum levels of liver enzymes and grade of hepatic steatosis in all study groups during the 12-week intervention period (all p < 0.010)
PMID 33081717 · one of two readings recorded this
patients with hepatic steatosis grade 1 (mild) at study endpoint
Grade 1 (mild steatosis) | 4 (17.4) | 18 (78.3) | 16 (69.6) | 13 (56.5)
PMID 33081717 · one of two readings recorded this
patients with hepatic steatosis grade 2 (moderate) at study endpoint
Grade 2 (moderate steatosis) | 0 (0.0) | 2 (8.7) | 3 (13.0) | 10 (43.5)
PMID 33081717 · one of two readings recorded this
serum ALP, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction
decreases
for ALP: mean difference − 39.2 IU/L
PMID 33081717 · one of two readings recorded this
serum ALP
decreases, p = 0.05
Multivariable adjusted | 137.1 [123.3; 150.8] | 150.0 [135.5; 164.4] | 163.1 [149.1; 177.2] | 176.2 [162.1; 190.4] | 0.050
PMID 33081717 · one of two readings recorded this
serum ALP
decreases, p = 0.009
Unadjusted | 136.1 [112.6; 159.5] | 142.7 [122.2; 163.3] | 167.1 [151.5; 182.7] | 180.6 [161.8; 199.3] | 0.009
PMID 33081717 · one of two readings recorded this
serum ALT, β-cryptoxanthin versus control, adjusted 12-week reduction
decreases, p = 0.005
for ALT: mean difference − 9.6 IU/L; p = 0.005
PMID 33081717 · one of two readings recorded this
serum ALT, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction
decreases
for ALT: mean difference − 27.2 IU/L
PMID 33081717 · one of two readings recorded this
serum ALT, HP-diet versus control, adjusted 12-week reduction
decreases, p = 0.05
for ALT: mean difference − 16.6 IU/L; and for GGT: mean difference − 7.5 IU/L; both p < 0.050
PMID 33081717 · one of two readings recorded this
serum ALT
decreases, p = 0.001
Multivariable adjusted | 25.1 [21.0; 29.3] | 35.7 [31.3; 40.1] | 42.7 [38.5; 47.0] | 52.4 [48.1; 56.6] | < 0.001
PMID 33081717 · one of two readings recorded this
serum ALT
decreases, p = 0.001
Unadjusted | 25.7 [20.9; 30.5] | 36.0 [30.2; 41.8] | 42.6 [37.9; 47.4] | 51.6 [47.6; 55.6] | < 0.001
PMID 33081717 · one of two readings recorded this
serum AST, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction
decreases
for AST: mean difference − 7.2 IU/L
PMID 33081717 · one of two readings recorded this
serum AST
decreases, p = 0.039
Multivariable adjusted | 18.9 [16.1; 21.7] | 20.7 [17.7; 23.6] | 23.8 [20.9; 26.7] | 26.0 [23.2; 28.9] | 0.039
PMID 33081717 · one of two readings recorded this
serum AST
no effect, p = 0.121
Unadjusted | 20.0 [17.5; 22.4] | 21.6 [19.8; 23.4] | 23.1 [21.0; 25.2] | 24.7 [20.2; 29.2] | 0.121
PMID 33081717 · one of two readings recorded this
serum β-cryptoxanthin
no effect, p = 0.943
Baseline | 0.16 [0.14; 0.18] | 0.16 [0.14; 0.18] | 0.15 [0.13; 0.17] | 0.16 [0.14; 0.18] | 0.943
PMID 33081717 · one of two readings recorded this
serum β-cryptoxanthin
increases, p = 0.001
Week 12 | 0.28 [0.25; 0.30] | 0.16 [0.14; 0.18] | 0.26 [0.23; 0.29] | 0.16 [0.14; 0.18] | < 0.001
PMID 33081717 · one of two readings recorded this
serum GGT, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction
decreases
for GGT: mean difference − 16.3 IU/L
PMID 33081717 · one of two readings recorded this
serum GGT, HP-diet versus control, adjusted 12-week reduction
decreases, p = 0.05
for ALT: mean difference − 16.6 IU/L; and for GGT: mean difference − 7.5 IU/L; both p < 0.050
PMID 33081717 · one of two readings recorded this
serum GGT
decreases, p = 0.001
Multivariable adjusted | 16.9 [13.5; 20.2] | 25.7 [22.2; 29.2] | 27.6 [24.2; 31.0] | 33.2 [29.7; 36.6] | < 0.001
PMID 33081717 · one of two readings recorded this
serum GGT
decreases, p = 0.001
Unadjusted | 17.0 [14.3; 19.7] | 25.5 [21.8; 29.2] | 27.8 [24.4; 31.2] | 33.0 [29.8; 36.3] | < 0.001
PMID 33081717 · one of two readings recorded this
weight loss as percent of baseline weight
decreases, p = 0.001
the corresponding values in the other groups (i.e., 3.9% in both β-cryptoxanthin and control groups) were significantly lower (all p < 0.001)
PMID 33081717 · one of two readings recorded this
weight loss as percent of baseline weight
decreases
patients in the HP-diet and β-cryptoxanthin and HP-diet groups had lost 6.8% and 6.9% of their baseline weight at study endpoint respectively
PMID 33081717 · one of two readings recorded this
depression, stress and anxiety scores
no effect
No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed
PMID 37242207 · one of two readings recorded this
gastrointestinal discomfort or headache
no effect
No gastrointestinal discomfort or headache was reported
PMID 37242207 · one of two readings recorded this
gene expression of RARA, RXRA, RXRB, BHLHE40, PPARD and ALDH1A1
no effect
Overall, 8 weeks of supplementation of β-cryptoxanthin up to 6 mg/day did not significantly change the gene expression of RARA, RXRA, RXRB, BHLHE40, PPARD, and ALDH1A1 in PBMCs
PMID 37242207 · one of two readings recorded this
gut microbial community diversity
no effect
There was no significant difference in microbial community diversity between the samples of the three different treatment groups before and after supplementation
PMID 37242207 · one of two readings recorded this
gut microbial composition
no effect
Overall, the results indicated that β-cryptoxanthin consumption of up to 6 mg/day had no significant effect on microbial composition compared with placebo
PMID 37242207 · one of two readings recorded this
mean compliance rate
The mean compliance rate was 95%
PMID 37242207 · one of two readings recorded this
physical activity and sleep patterns
no effect
No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed
PMID 37242207 · one of two readings recorded this
plasma beta-cryptoxanthin concentration at 2, 4 and 8 weeks, HPLC, 3 and 6 mg/day versus placebo (primary outcome); other endpoints read and left without a node or without a self-supporting between-arm sentence: plasma other carotenoids and retinol, PBMC retinol-signalling gene expression by qPCR, fecal microbiome 16S, GHQ12/QLES/STAI/DASS/PSS, accelerometer activity and PSQI sleep, safety laboratory panel
increases
Not recorded as a finding: this platform holds no node for the endpoint
At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001).
PMID 37242207 · one of two readings recorded this
plasma α-carotene concentration
increases
0.26 ± 0.43 µmol/L at week 8 vs. 0.09 ± 0.04 µmol/L at baseline for placebo
PMID 37242207 · one of two readings recorded this
plasma α-cryptoxanthin, β-carotene, lycopene, lutein, zeaxanthin and all-trans retinol concentrations
no effect
The mean plasma concentrations of the other carotenoids (α-cryptoxanthin, β-carotene, lycopene, lutein, and zeaxanthin) and all-trans retinol did not change with time in all three groups
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration, HPLC, at 2, 4 and 8 weeks (primary outcome); also plasma α-cryptoxanthin, α-carotene, β-carotene, lycopene, lutein, zeaxanthin and all-trans retinol by HPLC; PBMC retinol-signalling gene expression by qPCR; GHQ12, QLES, SWLS, STAI, DASS, PSS; actigraphy and PSQI; gut microbiome 16S
increases, significantly higher than control at 4 and 8 weeks in both the 3 and 6 mg/day groups
Not recorded as a finding: this platform holds no node for the endpoint
At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001).
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases, p = 0.001
At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001)
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases, p = 0.03
Further, the concentration of β-cryptoxanthin in the 6 mg/day group was significantly higher compared to that in the 3 mg/day group (p = 0.03)
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases
Following 2 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration increased to 3.5 ± 1.6 µmol/L from a baseline of 0.6 ± 0.5 µmol/L in the 3 mg/day group
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases
After 8 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration further increased to 6.0 ± 2.6 µmol/L in the 3 mg/day group and to 9.0 ± 4.1 µmol/L in the 6 mg/day group
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases
and to 4.2 ± 1.2 µmol/L from a baseline of 0.4 ± 0.2 µmol/L in the 6 mg/day group
PMID 37242207 · one of two readings recorded this
plasma β-cryptoxanthin concentration
increases
After 8 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration further increased to 6.0 ± 2.6 µmol/L in the 3 mg/day group and to 9.0 ± 4.1 µmol/L in the 6 mg/day group
PMID 37242207 · one of two readings recorded this
quality-of-life scores
no effect
No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed
PMID 37242207 · one of two readings recorded this
serious or severe adverse events and deaths
no effect
No serious or severe adverse events or deaths were observed
PMID 37242207 · one of two readings recorded this
study completion
n = 80
Overall, 89% of all randomized participants (n = 80) completed the study
PMID 37242207 · one of two readings recorded this
vital signs and laboratory parameters
no effect
No clinically significant changes in vital signs or laboratory parameters that were considered to be related to β-cryptoxanthin were observed after 8 weeks of supplementation of up to 6 mg/day
PMID 37242207 · one of two readings recorded this